Fiche publication
Date publication
août 2021
Journal
Viruses
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas
,
Dr VERRIER Eloi
Tous les auteurs :
Heuschkel MJ, Baumert TF, Verrier ER
Lien Pubmed
Résumé
Chronic hepatitis D is one of the most severe and aggressive forms of chronic viral hepatitis with a high risk of developing hepatocellular carcinoma (HCC). It results from the co-infection of the liver with the hepatitis B virus (HBV) and its satellite, the hepatitis D virus (HDV). Although current therapies can control HBV infection, no treatment that efficiently eliminates HDV is available and novel therapeutic strategies are needed. Although the HDV cycle is well described, the lack of simple experimental models has restricted the study of host-virus interactions, even if they represent relevant therapeutic targets. In the last few years, the discovery of the sodium taurocholate co-transporting polypeptide (NTCP) as a key cellular entry factor for HBV and HDV has allowed the development of new cell culture models susceptible to HBV and HDV infection. In this review, we summarize the main in vitro model systems used for the study of HDV entry and infection, discuss their benefits and limitations and highlight perspectives for future developments.
Mots clés
hepatitis B virus (HBV), hepatitis D virus (HDV), hepatoma cell lines, primary hepatocytes, sodium taurocholate co-transporting polypeptide (NTCP), viral cell entry
Référence
Viruses. 2021 Aug 3;13(8):
